主页 > 医学文档 >
【文摘发布】β受体阻断剂与糖尿病症状评分：
Author：McGill JB, Bakris GL, Fonseca V, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT Jr, Iyengar M, Anderson KM, Lukas MA, Dalal MR, Bell DS.
Resource: Diabetes Obes Metab. 2007 May;9(3):408-17.
Abstract：Aim: The Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial compared the metabolic effects of two beta-blockers in people with type 2 diabetes and hypertension treated with renin-angiotensin system (RAS) blockade and found differences in metabolic outcomes. In this paper, we report the results of a prespecified secondary analysis of GEMINI that sought to determine the effect of these two beta-blockers on commonly reported symptoms. Methods: The Diabetes Symptom Checklist (DSC), a self-report questionnaire measuring the occurrence and perceived burden of diabetes-related symptoms, was completed by GEMINI participants at baseline and at the end of the study (maintenance month 5). The DSC assessed symptoms in eight domains: psychology (fatigue), psychology (cognitive), neuropathy (pain), neuropathy (sensory), cardiology, ophthalmology, hyperglycaemia and hypoglycaemia. Results: Comparison of the mean change in self-reported diabetes-related symptoms indicated a significant treatment difference favouring carvedilol over metoprolol tartrate in overall symptom score (-0.08; 95% CI -0.15, -0.01; p = 0.02) and in the domains for hypoglycaemia symptoms (-0.12; 95% CI -0.23, -0.02; p = 0.02) and hyperglycaemia symptoms (-0.16; 95% CI -0.27, -0.05; p = 0.005). Carvedilol resulted in fewer perceived diabetes-related symptoms in patients with diabetes and hypertension. Conclusion: Carvedilol resulted in a lower perceived burden of diabetes-related symptoms in patients with type 2 diabetes and hypertension. The addition of a well-tolerated beta-blocker to RAS blockade may improve hypertension treatment and quality of life in patients with diabetes.
PMID: 17391169 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Title：beta-Blocker use and diabetes symptom score: results from the GEMINI study.
题目：β受体阻断剂与糖尿病症状评分：GEMINI研究结果
Author：McGill JB, Bakris GL, Fonseca V, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT Jr, Iyengar M, Anderson KM, Lukas MA, Dalal MR, Bell DS.
作者：McGill JB, Bakris GL, Fonseca V, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT Jr, Iyengar M, Anderson KM, Lukas MA, Dalal MR, Bell DS.
Resource: Diabetes Obes Metab. 2007 May;9(3):408-17.
来源：糖尿病，肥胖和代谢.2007年5月，9（3）：408-17
Abstract：摘要
Aim: The Glycemic Effect in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial compared the metabolic effects of two beta-blockers in people with type 2 diabetes and hypertension treated with renin-angiotensin system (RAS) blockade and found differences in metabolic outcomes. In this paper, we report the results of a prespecified secondary analysis of GEMINI that sought to determine the effect of these two beta-blockers on commonly reported symptoms.
目的： 对糖尿病血糖的影响：卡维地洛与美托洛尔在高血压患者的比较（GEMINI）试验，比较了高血压合并2型糖尿病患者在肾素-血管紧张素（RAS）系统阻断剂的基础上，应用卡维地洛和美托洛尔两种β-阻滞剂对于代谢方面的影响，发现结果确有差异。我们的研究结果基于GEMINI试验一项预先确定的次要分析，这个分析试图测定两种β-阻滞剂对于常见症状的影响。
Methods: The Diabetes Symptom Checklist (DSC), a self-report questionnaire measuring the occurrence and perceived burden of diabetes-related symptoms, was completed by GEMINI participants at baseline and at the end of the study (maintenance month 5). The DSC assessed symptoms in eight domains: psychology (fatigue), psychology (cognitive), neuropathy (pain), neuropathy (sensory), cardiology, ophthalmology, hyperglycaemia and hypoglycaemia.
方法：参加GEMINI试验的患者在基线水平和试验结束（持续5月）时，分别填写糖尿病症状核对表（DSC），一种测量糖尿病相关症状的发生率和感知症状的自评量表。该量表评估了8个领域的症状：心理（疲乏）、心理（认知）、神经（疼痛）、神经（感觉）、心脏、眼科、高血糖和低血糖。
Results: Comparison of the mean change in self-reported diabetes-related symptoms indicated a significant treatment difference favouring carvedilol over metoprolol tartrate in overall symptom score (-0.08; 95% CI -0.15, -0.01; p = 0.02) and in the domains for hypoglycaemia symptoms (-0.12; 95% CI -0.23, -0.02; p = 0.02) and hyperglycaemia symptoms (-0.16; 95% CI -0.27, -0.05; p = 0.005). Carvedilol resulted in fewer perceived diabetes-related symptoms in patients with diabetes and hypertension.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-09 17:11
医学,生命科学网